Matinas BioPharma Holdings, Inc. received a notice from NYSE American for failing to hold its annual stockholder meeting in 2024, but its stock will remain listed during the cure period until compliance is regained by December 31, 2025.
AI Assistant
MATINAS BIOPHARMA HOLDINGS INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.